In 7% to 10% of AML patients, loss-of-function mutations in TET2 were described; moreover, 10% to 20% of people with AML have heterozygous mutations in IDH1 and IDH2 that are mutually exclusive with mutations in TET2 [19]. This evidence concerns the gene IDH2 and acute myeloid leukemia.